论文部分内容阅读
虽然环孢菌素的使用已改善了肾,心和肝移植的移植物存活,但它对感染的发生率和严重性的影响仍不清楚。作者们回顾在他们医院接受环孢菌素或硫唑嘌呤的尸体肾移植患者一年内发生感染的发生率和严重性,同时也对比了糖尿病患者的这两种情况。从1982年12月到1984年的连续45例(男26,女19,平均年龄37.8±9.1岁)肾移植接受了硫唑嘌呤和强的松治疗。从1984年3月到1985年4月的连续40例尸体肾移植者是用环孢菌素及强的松治疗,其中3例改用硫唑嘌呤而未被列入统计分析,故环孢菌素治疗者仅37例(男25,女12,平均年龄37.±9.1岁)。硫唑嘌呤组糖尿病患者占25例(男12,女13,平均年龄37.4岁),环孢菌素组的糖尿病患者占24例(男18,女6,平均年龄37.8岁)。环孢
Although the use of cyclosporine has improved graft survival in kidney, heart and liver transplantation, its impact on the incidence and severity of infections remains unclear. The authors reviewed the incidence and severity of infections within one year of cadaveric renal transplant recipients who received cyclosporine or azathioprine in their hospital and also compared both of these conditions in patients with diabetes. Forty-five consecutive (male 26, female 19, mean age 37.8 ± 9.1 years) kidney transplants received azathioprine and prednisone from December 1982 to 1984. From March 1984 to April 1985, 40 consecutive cadaveric kidney transplant recipients were treated with cyclosporin and prednisone, and 3 of them were switched to azathioprine instead of included in the statistical analysis, Only 37 cases of treatment (male 25, female 12, mean age 37 ± 9.1 years). Azathioprine group 25 cases of diabetes (male 12, female 13, average age 37.4 years), cyclosporine group of patients with diabetes accounted for 24 cases (male 18, female 6, mean age 37.8 years). Cyclosporine